Karyopharm Therapeutics (NASDAQ:KPTI) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) in a research report report published on Thursday morning. The firm issued a hold rating on the stock.

KPTI has been the subject of a number of other reports. SVB Leerink reduced their price target on shares of Karyopharm Therapeutics from $6.00 to $5.00 and set a market perform rating for the company in a research report on Tuesday, January 10th. Morgan Stanley reduced their price target on shares of Karyopharm Therapeutics from $7.00 to $5.00 and set an equal weight rating for the company in a research report on Friday, January 27th. HC Wainwright reaffirmed a buy rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, February 22nd. Finally, Piper Sandler initiated coverage on shares of Karyopharm Therapeutics in a research report on Thursday, January 19th. They set an overweight rating and a $8.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Karyopharm Therapeutics has an average rating of Moderate Buy and an average target price of $9.50.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI traded down $0.02 during mid-day trading on Thursday, reaching $3.40. The company had a trading volume of 7,969,236 shares, compared to its average volume of 2,044,603. The stock has a fifty day moving average of $3.24 and a two-hundred day moving average of $4.15. Karyopharm Therapeutics has a 12-month low of $2.45 and a 12-month high of $8.63.

Karyopharm Therapeutics (NASDAQ:KPTI – Get Rating) last posted its quarterly earnings results on Wednesday, February 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.09). The firm had revenue of $33.58 million for the quarter, compared to analyst estimates of $33.88 million. Equities research analysts predict that Karyopharm Therapeutics will post -1.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Karyopharm Therapeutics

In other Karyopharm Therapeutics news, CFO Michael Mason sold 11,205 shares of the stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $3.03, for a total transaction of $33,951.15. Following the transaction, the chief financial officer now owns 245,361 shares in the company, valued at $743,443.83. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Karyopharm Therapeutics news, CEO Richard A. Paulson sold 33,033 shares of the stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $3.03, for a total transaction of $100,089.99. Following the transaction, the chief executive officer now owns 823,622 shares in the company, valued at $2,495,574.66. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Michael Mason sold 11,205 shares of the firm’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $3.03, for a total transaction of $33,951.15. Following the completion of the sale, the chief financial officer now owns 245,361 shares in the company, valued at approximately $743,443.83. The disclosure for this sale can be found here. Insiders have sold a total of 75,131 shares of company stock worth $229,983 over the last 90 days. Insiders own 10.24% of the company’s stock.

Institutional Investors Weigh In On Karyopharm Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY grew its stake in shares of Karyopharm Therapeutics by 73.9% in the third quarter. Metropolitan Life Insurance Co NY now owns 4,622 shares of the company’s stock worth $25,000 after acquiring an additional 1,964 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Karyopharm Therapeutics by 612.5% during the third quarter. Nisa Investment Advisors LLC now owns 5,700 shares of the company’s stock worth $26,000 after buying an additional 4,900 shares in the last quarter. Advisor Group Holdings Inc. boosted its stake in Karyopharm Therapeutics by 134.3% during the fourth quarter. Advisor Group Holdings Inc. now owns 8,906 shares of the company’s stock worth $30,000 after buying an additional 5,105 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in Karyopharm Therapeutics during the fourth quarter worth $34,000. Finally, Prelude Capital Management LLC acquired a new stake in Karyopharm Therapeutics during the second quarter worth $53,000. Institutional investors and hedge funds own 96.13% of the company’s stock.

About Karyopharm Therapeutics

(Get Rating)

Karyopharm Therapeutics, Inc is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).